Saman Daroo 8 is a knowledge-based subsidiary company of Endowment Beneficiary Foundation of Imam Reza shrine, which was founded in the northeastern Iranian city of Mashhad in October 2008. Subsequently, it embarked on a research project to produce the recombinant factor VIII products, and eventually produced the medication in 2015.

In 2020, the company expanded the scope of its activities and production, which resulted in  250- and 1000-unit doses.

Following, there is an interview with the CEO of the company, Dr Seyyed Ahmad Mohajeri:

Q: What is the significance of producing the recombinant factor VIII in the country?

A: Currently, the medication is available in two types: recombinant vs. plasma-derived; the former has been more widely welcomed by specialists and patients alike. In fact, the recombinant variation reduces the risks of transferring the virus via the medication, even to zero.

Q: What is the company’s present share in supplying the demands of hemophilic patients in the country?

A: Saman Daroo 8 is currently producing 45,000 vials of Safacto AF each month. Despite the fall in our production last year, we still have %50 of the national market for this medication.

Q: Given that a group of hemophilic patients still use the plasma-derived medication imported into the country, how can the production of recombinant Factor VIII save revenues for Iran?

A: The national consumption rate of this medication is some 500,000 vials yearly. If the domestic version is used instead, tens of millions of Euros will be saved.

Q: How will domestically-produced Factor VIII be distributed among patients in the country?

A: This medication is a product of Saman Daroo 8, based on permissions from Food and Drug Administration. Yara Teb Samen company is in charge of distributing the medication in the country. Hemophilic patients can get hold of it according to their allocated shares.

Q: Considering the complete supply of national demands by the company, what are the prospects for the export of this medication?

A: Exporting this product is very high on our agenda, and talks are underway with Iraq, Pakistan, Malaysia, etc. for export.

Q: How do you see the future for the domestic production of this medication?

A: Next year is very bright for Saman Daroo 8, as we have set our sights on totally cover the domestic demands.